Loading the comparison…
Loading the comparison…
Growth Hormone Axis
A selective growth-hormone secretagogue with a clean side-effect profile.
Growth Hormone Axis
The classic GH-stimulating pair in one vial.
Ipamorelin is not FDA-approved and rated 3/5 for evidence; CJC-1295 (no DAC) + Ipamorelin is not FDA-approved and rated 3/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for growth hormone axis goals.
Often used together: Already sold as a blend — a GHRH + GHRP pairing for synergy.
| Compare | Ipamorelin A selective growth-hormone secretagogue with a clean side-effect profile. | CJC-1295 (no DAC) + Ipamorelin The classic GH-stimulating pair in one vial. |
|---|---|---|
| Category | Growth Hormone Axis | Growth Hormone Axis |
| Evidence | 3/5Phase 2 human trials for postoperative ileus; GH-release effects are well documented in humans. | 3/5Each component studied in humans for GH release; the combined long-term outcomes data is thin. |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | NNC 26-0161 | Modified GRF 1-29 + Ipamorelin, CJC/Ipa blend |
| How it works | Ghrelin-receptor (GHS-R1a) agonist producing a short, pulsatile GH release. Often paired with a GHRH analog (CJC-1295, sermorelin) for a stronger combined pulse. | Two receptors, one pulse: GHRH-receptor stimulation (CJC-1295) plus ghrelin-receptor stimulation (ipamorelin) produces a larger-than-either GH release. Short half-life keeps the pulsatile pattern. |
| Half-life | About 2 hours | CJC no-DAC ≈ 30 min; ipamorelin ≈ 2 h |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Subcutaneous |
| Good once mixed | ~30 days in the fridge | ~21 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $3.00 (10 mg vial, 40% off) | $3.60 (10 mg vial, 40% off) |
| Latest lab purity | 99.79% (lot IPA0002) | 99.12% (lot CIP0003) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about Ipamorelin and CJC-1295 (no DAC) + Ipamorelin. It answers from these same pages, with links back here.
Ipamorelin is not FDA-approved and rated 3/5 for evidence; CJC-1295 (no DAC) + Ipamorelin is not FDA-approved and rated 3/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for growth hormone axis goals.
Ipamorelin: Not FDA-approved. CJC-1295 (no DAC) + Ipamorelin: Not FDA-approved. Regulations change, so confirm with the FDA.
Ipamorelin is rated 3 out of 5: Phase 2 human trials for postoperative ileus; GH-release effects are well documented in humans. CJC-1295 (no DAC) + Ipamorelin is rated 3 out of 5: Each component studied in humans for GH release; the combined long-term outcomes data is thin. The scale is explained on our methodology page.
Ipamorelin is banned by WADA, by name or as part of a named class. CJC-1295 (no DAC) + Ipamorelin is banned by WADA, by name or as part of a named class.
Already sold as a blend — a GHRH + GHRP pairing for synergy. That describes how some people use them, not a recommendation.